For 25 years, Ritedose has been a CDMO that’s provided sterile, aseptic production of single-dose medication for more than 8 billion doses. Novo Holdings has taken notice, acquiring the Columbia, GA…
After showcasing clinical data at #ASH21 for a sickle cell disease candidate, Sanofi has decided to throw in the towel on its 8-year partnership with collaborator Sangamo — and return its rights to…
VeriSIM Life has been working on creating a biosimulation platform since its founding in 2017 — and after more than four years and a pre-seed and seed round, the California software firm now has a…
Amgen is approaching the new year the same way it tackled 2021: swinging deals. But now it’s aiming to bring AI capabilities into the fold. The big biopharma is partnering with Flagship’s Generate…
Sosei Heptares is teaming up with a big-name partner: Alphabet’s Verily. No financials were disclosed, but the pair will aim to use Verily’s immune profiling and Sosei Heptares’ GPCR drug design…
Roger Perlmutter hasn’t wasted any time since announcing his supposed retirement from Merck in October 2020. After leaving his perch as one of the most successful R&D chiefs in Big Pharma, he’s now…
Eli Lilly is beefing up its fleet of vehicles being deployed to carry drugs to the brain. Enlisting Canada’s Entos Pharmaceuticals, Eli Lilly has grabbed rights to a suite of proteo-lipid vehicles…
A cell and gene therapy company is extending its collaboration with Seattle Children’s Hospital to establish manufacturing practices for cell therapy, the company announced Tuesday. BioLife’s new…
Alnylam was a few years ahead in the small interfering RNA (siRNA) space when Novartis jumped on the bandwagon in early 2020, licensing the company’s cholesterol-lowering drug Leqvio through its…
After a down year, biopharma writ large is looking for a breath of fresh air — and now the winds of change have hit oncology bispecifics player Zymeworks. Ali Tehrani, a co-founder of Zymeworks who…
